Written questions by Smith.

When the next review of the School Admissions Code will take place; and whether the scope of that review will include admissions arrangements for schools with a religious character, including the use of faith-based oversubscription criteria.

The department values the contribution schools with a religious character make to a diverse school system, and it is important faith schools can set admissions criteria that work for their local circumstances.The government set out in the ‘Every Child Achieving and Thriving’ White Paper its intention to consult later this year on changes to the statutory School Admissions Code to reduce barriers and promote fairness for families.Any changes to the School Admissions Code will be subject to a full public consultation and Parliamentary scrutiny.

When the Department plans to publish updated guidance on collective worship in state-funded schools in England; and whether there will be a public consultation as part of that review.

It has not proved possible to respond to the hon. Member in the time available before Prorogation.

When she expects to make a decision on whether to include Religious Education within the National Curriculum as part of the current curriculum and assessment review; and whether that decision will be subject to public consultation.

It has not proved possible to respond to the hon. Member in the time available before Prorogation.

What steps his Department is taking to make the drug Enhertu is available for people with secondary breast cancer in England.

I refer the Hon. Member to the answer I gave to the Hon. Member for East Grinstead and Uckfield on 13 January 2026 to Question 103810.

What progress has been made on the Cancer Plan commitment to define and count recurrent cancers, starting with metastatic breast cancer in 2026.

The National Disease Registration Service (NDRS) in NHS England collects, curates, quality assures, and analyses data about people with cancer across the whole of England.The NDRS data improvement team is working with National Health Service trusts to provide support and guidance to improve their reporting of non-primary cancers, focused on the specific recurrence and progression data fields included in the Cancer Outcomes and Services Dataset. This includes updates on trust submitted recurrence data in our routine ‘diagnoses by provider’ dashboard, available on our NHS facing, secure CancerStats2 site.The Government has set out in the National Cancer Plan for England an ambition to define and count recurrent cancers, starting with metastatic breast cancer from 2026. Existing data improvement activity within NDRS provides a foundation to support progress towards this ambition.

Whether the scheduled January meeting of the cross-government working group on how best to reduce barriers to clinical research with Schedule 1 drugs took place, and whether minutes will be available on public record.

A meeting of the cross-government working group on reducing barriers to research with Schedule 1 drugs took place on 23 January. The working group is comprised of officials from the relevant government departments and regulatory bodies. The group’s role is the formulation of policy. As such its considerations are not agreed government policy and we have no plans to publish them. The Government remains committed to implementing the recommendations of the Advisory Council on the Misuse of Drugs on reducing barriers to research with Schedule 1 drugs and we will publish our plans in this area in due course.

If she will list the meetings scheduled for the working group on any new issues involving research with controlled drugs during the next six months.

On 16 July, the Government responded to recommendations from the Advisory Council on the Misuse of Drugs (‘ACMD’) on how best to reduce barriers to clinical research with Schedule 1 drugs. The Government committed to set up a cross-government working group of officials to assist with delivery of those recommendations.The group had its first meeting in September, followed by a series of bilateral discussions between Home Office officials and the organisations represented on the working group. The next meeting is planned for January. Alongside the working group, officials have ongoing engagement with relevant officials in wider departments and agencies, and with businesses, representative organisations and researchers who are likely to benefit from the proposals. Officials have also explored with international counterparts the provisions for research with controlled drugs in their jurisdictions.

How many meetings have been held of the cross-government officials working group on research with controlled drugs.

On 16 July, the Government responded to recommendations from the Advisory Council on the Misuse of Drugs (‘ACMD’) on how best to reduce barriers to clinical research with Schedule 1 drugs. The Government committed to set up a cross-government working group of officials to assist with delivery of those recommendations.The group had its first meeting in September, followed by a series of bilateral discussions between Home Office officials and the organisations represented on the working group. The next meeting is planned for January. Alongside the working group, officials have ongoing engagement with relevant officials in wider departments and agencies, and with businesses, representative organisations and researchers who are likely to benefit from the proposals. Officials have also explored with international counterparts the provisions for research with controlled drugs in their jurisdictions.